Results 311 to 320 of about 9,882,917 (355)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 2010
Evidence-based, peer reviewed, best practice management guidelines for neurologists Diagnosis is only part of the puzzle. Effective treatment is what your patients really want. The European Federation of Neurological Societies has been publishing management guidelines in the European Journal of Neurology for many years.
Henry W, Querfurth, Frank M, LaFerla
+8 more sources
Evidence-based, peer reviewed, best practice management guidelines for neurologists Diagnosis is only part of the puzzle. Effective treatment is what your patients really want. The European Federation of Neurological Societies has been publishing management guidelines in the European Journal of Neurology for many years.
Henry W, Querfurth, Frank M, LaFerla
+8 more sources
American Journal of Hospice and Palliative Medicine®, 1992
Alzheimer's disease is one of the most severe and most common chronic diseases of older persons. Because occurrence of the disease is strongly related to age, its public health impact is likely to continue to increase as the population ages. As with many other diseases, a diagnosis of Alzheimer's disease is made through a combination of clinical ...
D A, Bennett, D A, Evans
+7 more sources
Alzheimer's disease is one of the most severe and most common chronic diseases of older persons. Because occurrence of the disease is strongly related to age, its public health impact is likely to continue to increase as the population ages. As with many other diseases, a diagnosis of Alzheimer's disease is made through a combination of clinical ...
D A, Bennett, D A, Evans
+7 more sources
Annual Review of Medicine, 1985
Significant progress has been made in identifying changes in cholinergic, monoaminergic, and peptidergic neurotransmitter systems in the brains of individuals with Alzheimer's disease. Moreover, neurobiological approaches are beginning to reveal the relationships between these neurotransmitter abnormalities and histological hallmarks of the disease, i ...
D L, Price +2 more
+9 more sources
Significant progress has been made in identifying changes in cholinergic, monoaminergic, and peptidergic neurotransmitter systems in the brains of individuals with Alzheimer's disease. Moreover, neurobiological approaches are beginning to reveal the relationships between these neurotransmitter abnormalities and histological hallmarks of the disease, i ...
D L, Price +2 more
+9 more sources
Nature Reviews Disease Primers, 2015
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8-10 years. The disease has an estimated prevalence of 10-30% in the population >65 years of age with an incidence of 1-3%.
Colin L, Masters +5 more
+7 more sources
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8-10 years. The disease has an estimated prevalence of 10-30% in the population >65 years of age with an incidence of 1-3%.
Colin L, Masters +5 more
+7 more sources